Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Follow the Journey
Companies On The Road
Arcadis DPS Group
C2 Pharma
CAI
EcoLab
Environmental Systems Corporation
Federal Equipment Company
Globyz Biopharma Services
Grifols
Integrity
Nu-Tek BioSciences
PHARMALEX
Waters Corporation
Follow the Journey
Companies On The Road
ABS
aCGT Vector
Alconox Inc.
Andelyn Biosciences
Arranta Bio
Avid Bioservices
BDD
BIOVECTRA
DPS Group
Dynamk Capital
Environmental Systems Corporation
Federal Equipment Company
Genesis AEC
Globyz Biopharma Services
Grifols Partnership
IDT Biologika
Inceptor Bio
IPS-Integrated Project Services
Kineticos Life Sciences
MilliporeSigma
Montana BioScience Alliance
Olon
Rentschler Biopharma
SanaClis
Scorpion Biological Services
Secant Group
Tapemark
VITRONIC
Follow the Journey
Companies On The Road
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Magazine
Archive
Reports
Nice Insight Reports
2022 Sterile
2023 Cell & Gene Therapy
2023 mAb and Recombinant Protein
2024 API
2024 OSD
2024 ADC
2024 mRNA
2024 Mammalian Cell Culture
2024 Microbial Cell Culture
2024 Plasmids
2024 Gene Therapy
2024 Cell Therapy
2024 Sterile
Community
Company A to Z
Follow the Journey
Companies On The Road
Follow The Artist
Follow the Journey
Companies On The Road
More+
Staffing
Media Kit
Teva
20 Articles Available
Can't find what you're looking for? Try our
advanced search
.
Recall
Teva Pharmaceuticals USA, Inc. Initiates Voluntary Nationwide Recall of Metformin Hydrochloride
PR-M06-20-NI-025
EpiPen
Teva Announces Availability of a Generic Equivalent of EpiPen Jr in the United States
PR-M08-19-NI-069
M&A
FLAMMA Acquires Teva’s Philadelphia cGMP Facility Marking Entry into the US Marketplace with Labs & Pilot Plant
PR-M07-19-NI-013
Generics
Teva Announces Launch of a Generic Version of Tarceva® (erlotinib) Tablets in the United States
PR-M05-19-NI-045
Clinical Development
Teva Announces Update on Fremanezumab Clinical Development for use in Episodic Cluster Headache
PR-M04-19-NI-077
Generics
Teva Announces Launch of a Generic Version of VESIcare® (solifenacin succinate) Tablets in the United States
PR-M04-19-NI-072
Generics
Teva Announces Launch of ALYQ™ (Tadalafil Tablets USP), a Generic Version of ADCIRCA® in the United States
PR-M02-19-NI-014
Drug Development
EMA Committee Recommends Approval of Teva’s Anti-CGRP Treatment for Migraines
PAO-M02-19-NI-003
FDA
Another Biosimilar Gets Nod from Independent FDA Panel
PAO-M10-18-NI-018
Study Results
Regeneron and Teva Announce Positive Topline Phase 3 Fasinumab Results in Patients with Chronic Pain from Osteoarthritis of the Knee or Hip
PR-M09-18-NI-059
Study Results
Teva and Regeneron Announce Positive Topline Phase 3 Fasinumab Results in Patients with Chronic Pain from Osteoarthritis of the Knee or Hip
PR-M09-18-NI-051
Announcement
Governor Murphy Announces Teva Pharmaceuticals to Locate US Headquarters in New Jersey
PR-M07-18-NI-025
Drug Discovery
TEVA Hopes to Launch New Migraine Drug Immediately After PDUFA Date
PAO-M05-18-NI-020
Clinical Data
Teva Presents New Long-Term Data Demonstrating Efficacy and Safety of COPAXONE® (glatiramer acetate injection) 40 mg/mL
PR-M05-18-NI-013
Generic
Teva Announces the Launch of a Generic Version of Lialda® in the United States
PR-M03-18-NI-100
Drug Development
Sosei Regains Worldwide Rights from Teva to Develop and Commercialize Novel Small Molecule CGRP Antagonists for Migraine and Other Severe Headaches
PR-M03-18-NI-054
Inhalation
Teva Announces U.S. Launch of QVAR® RediHaler™ (Beclomethasone Dipropionate HFA) Inhalation Aerosol
PR-M02-18-NI-53
Generics
Teva Announces Launch of a Generic Version of Syprine® in the United States
PR-M02-18-NI-050
FDA Approval
Teva Announces U.S. FDA Approval of TRISENOX® (arsenic trioxide) Injection for First Line Treatment of Acute Promyelocytic Leukemia
PR-M01-18-NI-053
Drug Development
Teva Announces Sale of PARAGARD® (intrauterine copper contraceptive) to CooperSurgical
PR-M08-17-NI-014
.svg)
